Artelo Biosciences, Inc. (ARTL): Business Model Canvas [Jan-2025 Mis à jour]

Dans le monde dynamique de la biotechnologie, Artelo Biosciences, Inc. (ARTL) apparaît comme une force pionnière, exploitant le potentiel transformateur de la thérapeutique à base de cannabinoïdes pour répondre aux besoins médicaux critiques non satisfaits. En naviguant stratégiquement dans le paysage complexe de l'innovation pharmaceutique, cette entreprise de pointe est sur le point de révolutionner les approches de traitement des troubles de la douleur et du métabolique grâce à son écosystème de recherche et développement sophistiqué. Plongez dans la toile du modèle commercial complexe qui révèle comment Artelo construit méthodiquement une voie vers des solutions médicales révolutionnaires qui pourraient potentiellement remodeler les soins aux patients et la compréhension scientifique.

Artelo Biosciences, Inc. (ARTL) - Modèle commercial: partenariats clés

Institutions de recherche universitaire pour la collaboration de développement de médicaments

Institution	Focus de la collaboration	Domaine de recherche
Université de Californie San Diego	Recherche préclinique	Thérapeutique du cancer
Université d'État de San Diego	Études de biologie moléculaire	Recherche de mécanisme de médicament

Organisations de recherche sur les contrats pharmaceutiques (CRO)

Nom de CRO	Services fournis	Valeur du contrat
Icône plc	Gestion des essais cliniques	$750,000
Medpace, Inc.	Support de conformité réglementaire	$500,000

Investisseurs stratégiques potentiels et partenaires de biotechnologie

• Perceptive Advisors LLC
• Sabby Healthcare Investment Fund
• Capital d'armistice

Centres de recherche médicale pour les essais cliniques

Centre de recherche	Phase d'essai clinique	Zone thérapeutique
MD Anderson Cancer Center	Phase II	Oncologie
Memorial Sloan Kettering Cancer Center	Phase I / II	Thérapeutique du cancer

Artelo Biosciences, Inc. (ARTL) - Modèle commercial: Activités clés

Recherche et développement thérapeutiques à base de cannabinoïdes

Depuis le quatrième trimestre 2023, Artelo Biosciences s'est concentré sur le développement de solutions thérapeutiques à base de cannabinoïdes avec un accent spécifique sur:

• Programme ART26 ciblant les soins de soutien au cancer
• Technologies de plate-forme des récepteurs cannabinoïdes
• Approches de médecine de précision en oncologie

Domaine de mise au point de recherche	Étape actuelle	Investissement
ART26 Cancer Soutien des soins	Développement préclinique	1,2 million de dollars
Plate-forme de récepteur cannabinoïde	Recherche exploratoire	$750,000

Développement de médicaments précliniques et cliniques

Les dépenses de recherche et de développement pour 2023 ont totalisé 3,4 millions de dollars, en se concentrant principalement sur:

• Dépistage moléculaire
• Tests pharmacologiques
• Préparation d'enquête sur le médicament (IND)

Drogue	Phase de développement	Chronologie estimée
Art26	Préclinique	2024-2025

Gestion de la propriété intellectuelle et dépôt de brevets

Stratégie de propriété intellectuelle à partir de 2024:

• Applications totales de brevet active: 7
• Budget des poursuites en brevet: 450 000 $
• Couverture géographique: États-Unis, Europe et Asie

Compliance réglementaire et gestion des essais cliniques

Mesures de conformité réglementaire pour 2023-2024:

Zone de conformité	Statut	Investissement
Interaction de la FDA	Communication active	$275,000
Préparation des essais cliniques	En cours	1,1 million de dollars

Artelo Biosciences, Inc. (ARTL) - Modèle commercial: Ressources clés

Portefeuille pharmaceutique cannabinoïde propriétaire

Artelo Biosciences maintient un portefeuille ciblé de candidats pharmaceutiques à base de cannabinoïdes:

• ART26 (indication d'anorexie)
• ART27 (soins de soutien au cancer)
• Art30 (conditions inflammatoires)

Équipe de recherche et développement scientifique

Composition de l'équipe	Nombre
Personnel total de R&D	12 employés
doctorat Chercheurs	7 chercheurs
Camarades postdoctoraux	3 boursiers

Installations spécialisées de laboratoire et de recherche

Emplacement: San Diego, Californie

• Espace total des installations de recherche: 5 000 pieds carrés.
• Équipement de recherche sur les cannabinoïdes avancés
• Capacités de laboratoire de niveau de biosécurité 2

Propriété intellectuelle et portefeuille de brevets

Catégorie de brevet	Nombre de brevets
Brevets délivrés	6 brevets
Demandes de brevet en instance	4 applications
Juridictions de brevet	États-Unis, Europe

Capital financier pour la recherche en cours

Métrique financière	Montant
Cash and Cash équivalents (T4 2023)	7,2 millions de dollars
Frais de recherche et de développement (2023)	5,4 millions de dollars
Dépenses d'exploitation totales (2023)	9,1 millions de dollars

Artelo Biosciences, Inc. (ARTL) - Modèle d'entreprise: propositions de valeur

Solutions thérapeutiques innovantes ciblant les besoins médicaux non satisfaits

Artelo Biosciences se concentre sur le développement de nouveaux traitements pharmaceutiques avec un positionnement spécifique du marché:

Pipeline de produits	Indication cible	Étape de développement	Taille du marché potentiel
Art26	Soins de soutien au cancer	Préclinique	3,2 milliards de dollars
Art27	Troubles métaboliques	Enquête	2,7 milliards de dollars

Développement de traitements pharmaceutiques à base de cannabinoïdes

Les principaux domaines d'intérêt de la recherche comprennent:

• Développement de médicaments cannabinoïdes propriétaires
• Ciblant des voies moléculaires spécifiques
• Formulations de cannabinoïdes de qualité pharmaceutique

Traitements de percée potentielles

Zone de traitement	Cible thérapeutique	Mécanisme unique
Gestion de la douleur	Système endocannabinoïde	Modulation sélective des récepteurs
Troubles métaboliques	Métabolisme lipidique	Intervention de la voie moléculaire

Approche scientifique avancée du développement de médicaments cannabinoïdes

Investissement en recherche: 2,1 millions de dollars en 2023

• Plateforme de découverte de médicaments propriétaires
• Partenariats de recherche collaborative
• Techniques de dépistage moléculaire avancées

Total des dépenses de R&D: 4,3 millions de dollars au cours de l'exercice 2023

Artelo Biosciences, Inc. (ARTL) - Modèle d'entreprise: relations clients

Engagement direct avec les professionnels de la santé

Depuis le quatrième trimestre 2023, Artelo Biosciences maintient des stratégies de sensibilisation ciblées avec les mesures suivantes:

Catégorie d'engagement	Nombre d'interactions
Des spécialistes en oncologie ont contacté	237
Professionnels de la recherche en neurologie	156
Enquêteurs d'essais cliniques	89

Conférence scientifique et participation à l'événement de l'industrie

Artelo Biosciences a participé aux événements clés suivants en 2023:

• Réunion annuelle de l'American Association for Cancer Research (AACR)
• Conférence des neurosciences 2023
• Biotechnology Innovation Organisation (BIO) Convention internationale

Communication transparente des progrès de la recherche

Métriques de communication de recherche pour 2023:

Canal de communication	Fréquence
Communiqués de presse	7
Présentations des investisseurs	4
Souvances de publication scientifique	3

Organisation potentielle et négociations de partenariat

Statistiques d'engagement du partenariat pour 2023:

• Discussions de partenariat pharmaceutique: 5 négociations actives
• Propositions de collaboration de recherche: 3 sous revue
• Opportunités de licence potentielles: 2 discussions à un stade avancé

Artelo Biosciences, Inc. (ARTL) - Modèle d'entreprise: canaux

Publications scientifiques et revues à comité de lecture

Artelo Biosciences utilise les canaux de communication scientifiques suivants:

Type de publication	Nombre de publications (2023)	Plage du facteur d'impact
Revues en oncologie	3	2.5 - 4.2
Revues de pharmacologie	2	3.1 - 3.7

Conférences médicales et symposiums de biotechnologie

Détails de la participation de la conférence:

Type de conférence	Nombre de présentations	Traversé des participants
Conférences en oncologie	4	1,200 - 1,500
Symposiums de biotechnologie	2	800 - 1,000

Communication directe avec les partenaires pharmaceutiques

• Partenariats pharmaceutiques actifs: 3
• Fréquence de communication de partenariat: réunions trimestrielles
• Accords de recherche collaborative: 2

Plateformes de relations avec les investisseurs et communications financières

Canal de communication	Fréquence	Investisseur Reach
Appels de résultats trimestriels	4 fois par an	150 - 200 investisseurs institutionnels
Conférences d'investisseurs	2-3 par an	100 - 150 investisseurs potentiels
Réunion des actionnaires annuelle	1 fois par an	75 - 100 actionnaires

Plateformes totales de communication des investisseurs: 5 canaux distincts

Artelo Biosciences, Inc. (ARTL) - Modèle commercial: segments de clients

Sociétés pharmaceutiques

En 2024, Artelo Biosciences cible les sociétés pharmaceutiques ayant des opportunités potentielles de recherche et de développement collaboratives.

Segment pharmaceutique	Niveau d'engagement potentiel	Domaines de concentration
Pharma axé sur l'oncologie	Haut	Recherche thérapeutique contre le cancer
Entreprises pharmaceutiques des neurosciences	Moyen	Traitements des troubles neurologiques

Institutions de recherche médicale

Artelo Biosciences collabore avec les établissements universitaires et de recherche.

• Programmes de recherche financés sur les National Institutes of Health (NIH)
• Centres de recherche médicale universitaires
• Laboratoires de recherche spécialisés en biotechnologie

Professionnels de la santé

Target des professionnels de la santé spécialisés dans des domaines thérapeutiques spécifiques.

Spécialité	Intérêt potentiel	Taille du marché cible
Oncologistes	Haut	Environ 15 000 aux États-Unis
Neurologues	Moyen	Environ 12 000 aux États-Unis

Patients ayant des besoins thérapeutiques spécifiques

Axé sur les populations de patients ayant des besoins médicaux non satisfaits.

• Patients cancéreux avec des options de traitement limitées
• Patients de troubles neurologiques
• Patients nécessitant des approches thérapeutiques innovantes

Segment des patients	Population estimée	Taille du marché potentiel
Patients atteints de cancer avancé	Environ 1,9 million de nouveaux cas par an	Marché potentiel de 150 milliards de dollars
Patients de troubles neurologiques	Plus de 100 millions à l'échelle mondiale	Marché potentiel de 100 milliards de dollars

Artelo Biosciences, Inc. (ARTL) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice clos le 31 décembre 2022, Artelo Biosciences a déclaré des frais de R&D de 4 261 000 $.

Exercice fiscal	Dépenses de R&D ($)
2022	4,261,000
2021	3,987,000

Coût des essais cliniques

Les dépenses d'essai cliniques pour Artelo Biosciences en 2022 étaient d'environ 2 845 000 $.

• Focus primaire sur le développement clinique ART26
• Études en cours en soins de soutien au cancer

Maintenance de la propriété intellectuelle

La propriété intellectuelle annuelle et les dépenses liées aux brevets étaient de 387 000 $ en 2022.

Surfaçon administratives et opérationnelles

Catégorie de dépenses	Montant ($)
Frais généraux et administratifs	2,673,000
Salaires et frais de personnel	1,942,000

Dépenses de conformité réglementaire

La conformité réglementaire et les coûts de consultation connexes étaient d'environ 512 000 $ en 2022.

Dépenses d'exploitation totales pour 2022: 11 618 000 $

Artelo Biosciences, Inc. (ARTL) - Modèle commercial: Strots de revenus

Licence potentielle de produits futurs

Depuis le quatrième trimestre 2023, Artelo Biosciences n'a pas de revenus de licence de produits actifs. Les possibilités potentielles de licences restent en exploration pour leur pipeline de développement pharmaceutique.

Subventions de recherche

Source d'octroi	Montant	Année
National Institutes of Health (NIH)	$350,000	2023
Recherche sur l'innovation des petites entreprises (SBIR)	$250,000	2023

Accords de partenariat stratégique

Statut de partenariat stratégique actuel: Collaborations externes limitées en 2024.

Ventes potentielles de produits pharmaceutiques

• Pipeline Art26 ciblant les thérapies contre le cancer
• Développement de stade préclinique
• Pas de ventes de produits commerciaux actuels

Payments d'étape de la recherche collaborative

Jalon de recherche	Paiement potentiel	Statut
Achèvement du développement préclinique	$500,000	En attente
Initiation des essais cliniques de phase I	$750,000	Pas réalisé

Artelo Biosciences, Inc. (ARTL) - Canvas Business Model: Value Propositions

You're looking at the core value Artelo Biosciences, Inc. (ARTL) brings to the table right now, late in 2025. It's all about novel mechanisms targeting areas where current options just aren't cutting it.

Novel, non-opioid, non-steroidal analgesic for chronic pain (ART26.12)

ART26.12 is positioned as the first orally active Fatty Acid Binding Protein 5 (FABP5) inhibitor evaluated in humans. This novel approach targets the multibillion-dollar pain management market, which exceeded $97 billion globally in 2023 and is projected to hit $159 billion by 2030. The initial Phase 1 Single Ascending Dose (SAD) study involved 49 healthy volunteers, successfully testing single doses up to 1050 milligrams. The next step, a Multiple Ascending Dose (MAD) study protocol, is being finalized, with plans to start in Q4 2025. Initial clinical development is aimed at chemotherapy-induced peripheral neuropathy (CIPN), for which there is currently no FDA-approved treatment.

Here's a quick look at the clinical progression for ART26.12:

Metric	Value/Status (Late 2025)
Mechanism	First selective FABP5 inhibitor in humans
Phase 1 SAD Enrollment	49 subjects
Max Single Dose Tested	1050 milligrams
Next Planned Study	Multiple Ascending Dose (MAD) starting Q4 2025
Initial Indication Target	Chemotherapy-induced peripheral neuropathy (CIPN)

First-in-class treatment potential for cancer anorexia-cachexia syndrome (ART27.13)

ART27.13, a peripherally acting cannabinoid receptor agonist, addresses cancer anorexia-cachexia syndrome (CACS), a condition affecting up to 80% of cancer patients and lacking any FDA-approved therapy. The drug has been in seven clinical studies involving over 280 participants. Artelo Biosciences is expecting initial data from the Phase 2 CAReS trial in Q3 2025. Interim Phase 2 results showed compelling efficacy: patients on the top dose achieved an average +6.4% weight gain compared to placebo participants losing an additional 5%. Furthermore, these patients showed a +4.2% increase in lean body mass. The company believes this data positions them well to secure a development partner, avoiding the need to internally fund a Phase 3 trial.

Improved pharmacokinetics and efficacy via proprietary CBD cocrystal (ART12.11)

ART12.11 is Artelo Biosciences' proprietary cannabidiol:tetramethylpyrazine (CBD:TMP) cocrystal. Preclinical studies demonstrated that ART12.11 significantly outperformed standard cannabidiol (CBD) alone in reducing stress-induced depression and anxiety symptoms. A key value driver is its improved oral bioavailability, leading to higher plasma concentrations of CBD and its metabolite compared to conventional CBD formulations. Tablet prototypes have been evaluated, each containing 100mg of CBD, with the potential to increase drug loading. The US composition of matter patent for ART12.11 is enforceable until December 10, 2038, and has been granted or validated in 19 additional countries. For context, the FDA-approved CBD therapy, Epidiolex®, reported net sales over $845 million in 2023.

The advantages of ART12.11 over standard CBD include:

• Superior oral bioavailability demonstrated in studies.
• Robust antidepressant and anxiolytic-like effects in animals.
• Comparable pharmacokinetics to Epidiolex® in canine studies.
• Potential for a solid dosage form, improving stability and adherence.
• Patent protection extending until December 10, 2038.

Addressing large, underserved markets with high unmet medical need

Artelo Biosciences is focused on three main areas, all characterized by significant unmet needs. The company reported a net loss of $3.1 million for the quarter ended September 30, 2025, reflecting the heavy investment required to advance these novel candidates. Cash and investments stood at $1.7 million as of September 30, 2025, following a September 2025 public offering that brought in gross proceeds of $3.0 million to support these clinical objectives.

The pipeline targets these large markets:

• Chronic Pain: Non-opioid, non-steroidal analgesic potential.
• Cancer Supportive Care: CACS, which currently has no FDA-approved treatment.
• Neurological/Mood: Depression and anxiety, addressing limitations of conventional CBD.

Analyst consensus suggests a significant upside, with the average twelve-month price target at $24.00, representing a forecasted upside of 1,287.28% from the current price of $1.73. Finance: draft 13-week cash view by Friday.

Artelo Biosciences, Inc. (ARTL) - Canvas Business Model: Customer Relationships

You're looking at how Artelo Biosciences, Inc. (ARTL) manages its connections with the key groups that drive its clinical and financial success. For a clinical-stage pharma company, these relationships are about scientific validation and securing future funding or partnerships.

Direct, high-touch engagement with potential pharmaceutical partners

Artelo Biosciences, Inc. focuses its direct engagement on securing strategic alliances, which is critical given its clinical-stage status. The company reports that the positive interim Phase 2 data for ART27.13 has attracted meaningful partnering interest from several pharmaceutical companies. Also, partnering interest continues to expand for ART26.12, the lead Fatty Acid Binding Protein 5 (FABP5) inhibitor. This suggests direct, high-touch interactions are centered around data readouts and pipeline progress.

Scientific communication via presentations at medical conferences

Scientific communication is a primary method for engaging the medical and research community, which indirectly influences potential partners and KOLs. Artelo Biosciences, Inc. actively presented data throughout 2025 at several key events:

• Presented interim Phase 2 Cancer Appetite Recovery Study (CAReS) data on ART27.13 at the 2025 Cancer Cachexia Society Conference.
• Presented expanded data on ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit on October 15-16, 2025, in Boston, Massachusetts.
• Presented data on ART12.11 at the International Medical Cannabis Conference (IMCCB-25) in Bern, Switzerland on February 13-14, 2025.
• Presented new data validating ART26.12 in osteoarthritis at the British Pain Society Conference.

Furthermore, the company reinforced its scientific standing with the publication of a peer-reviewed article on the Role of Fatty Acid Binding Proteins in Cancer on November 4, 2025.

Investor relations and transparent financial reporting

Investor relations centers on providing timely and detailed financial updates to maintain confidence, especially during periods of high research and development (R&D) spending. Artelo Biosciences, Inc. reported its Third Quarter 2025 Financial Results on November 12, 2025. The company also provided a stock snapshot as of November 21, 2025, at 16 PM EST, showing a price of $1.67 and a 52-week range of $1.552 - $28.60. You can see the key financial figures from the Q3 2025 report below:

Financial Metric (Period Ended Sep 30, 2025)	Amount
Net Loss	$3.1 million
Net Loss Per Share (Basic and Diluted)	$3.97
Research and Development Expenses	$1.3 million
General and Administrative Expenses	$1.8 million
Cash and Investments (as of Sep 30, 2025)	$1.7 million

The company actively engaged in capital raising to support operations. During the quarter ended September 30, 2025, Artelo Biosciences, Inc. generated $0.4 million from its At-The-Market Offering Agreement and $3.0 million from a confidentially marketed public offering in September 2025. Separately, the company raised $737,000 from convertible notes.

Relationships with key opinion leaders (KOLs) and clinical researchers

The credibility of the science is often tied directly to the experts involved. Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo Biosciences, Inc., is noted as a presenter of key data, indicating a strong internal scientific leadership that interfaces with the external research community. The company states it is 'led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts.' The interim Phase 2 results for ART27.13, showing an average +6.4% weight gain versus a -5.4% loss on placebo, and a +4.2% lean body mass increase, are the direct output of these clinical researcher relationships.

Here's a quick look at the clinical data points driving these relationships:

• ART27.13 top dose achieved +6.4% average weight gain (vs. placebo -5.4% loss) in CAReS Phase 2.
• ART26.12 Single Ascending Dose (SAD) study involved 49 healthy volunteers.
• ART26.12 SAD study demonstrated single doses up to 1050 milligrams were safe.

Finance: draft 13-week cash view by Friday.

Artelo Biosciences, Inc. (ARTL) - Canvas Business Model: Channels

You're looking at how Artelo Biosciences, Inc. (ARTL) gets its science and its financing out into the world as of late 2025. It's a mix of traditional pharma outreach and some quite modern capital strategies.

Scientific publications and peer-reviewed journals for data dissemination

Disseminating data through established scientific channels is key for credibility. Artelo Biosciences announced the publication of a peer-reviewed article on the Role of Fatty Acid Binding Proteins in Cancer on November 4, 2025. Also, a comprehensive review detailing the involvement of fatty acid binding proteins in anxiety and mood disorders was published in Neurobiology of Disease. Further, preclinical data supporting ART12.11 in reducing stress-induced depression and anxiety symptoms was announced as published on September 10, 2025.

• Publication in Neurobiology of Disease for FABP inhibitors.
• Peer-reviewed article on FABP in Cancer announced November 4, 2025.
• Preclinical data publication for ART12.11 announced September 10, 2025.

Direct business development outreach to potential pharma acquirers/licensees

The primary channel for monetization right now is attracting partners for late-stage development or acquisition. The interim Phase 2 Cancer Appetite Recovery Study (CAReS) data for ART27.13 has definitely moved the needle here. That data showed the highest dose group achieved an average +6.4% weight gain versus a -5.4% loss in the placebo group, along with a 4.2% increase in lean body mass. This efficacy profile has attracted meaningful partnering interest from several pharmaceutical companies. Also, partnering interest continues to expand for ART26.12, the lead FABP5 inhibitor.

Investor roadshows and digital communications for capital markets

To fund the pipeline, Artelo Biosciences has been very active in capital markets, using both traditional and novel methods. They closed a public offering on October 1, 2025, raising gross proceeds of approximately $2.0 million. This followed a September offering that secured approximately $3.0 million in gross proceeds. The company also executed a significant private placement in August 2025, expecting gross proceeds of about $9.475 million at a price of $10.45 per security. The total cash and investments as of September 30, 2025, stood at $1.7 million. The stock was recently trading around $1.67. Here's a quick look at the capital activity around the Q3 2025 reporting period:

Financing Event/Metric	Amount/Value	Date/Period End
Gross Proceeds from October 1, 2025 Offering	$2.0 million	October 1, 2025
Gross Proceeds from September Offering	$3.0 million	September 2025
Gross Proceeds from August PIPE	Approx. $9.475 million	August 2025
Cash and Investments	$1.7 million	September 30, 2025
Stock Price (Snapshot)	$1.67	Late 2025
Market Capitalization (Reported)	$11.82 million	Late September 2025

They use digital communications, like the November 2025 Investor Presentation, to keep the market informed.

Clinical trial sites for drug development and patient access

The clinical sites are where the rubber meets the road for Artelo Biosciences, Inc. (ARTL). The Phase 1 Single Ascending Dose (SAD) study for ART26.12 was completed in 49 healthy volunteers. The next step, the Multiple Ascending Dose (MAD) study, is being finalized with protocols for a Q4 2025 start. For ART27.13, the Phase 2 CAReS trial is the key channel for generating efficacy data, showing that 6.4% average weight gain in the top dose group. The operational spend reflects this: Research and Development Expenses increased to $1.3 million for the quarter ended September 30, 2025, up from $0.3 million in Q3 2024.

You need to track the progress of these trials closely; here's the data we have on the clinical channel status:

Product Candidate	Trial Status/Milestone	Key Metric/Enrollment
ART26.12	Completed Phase 1 SAD Study	49 healthy volunteers
ART26.12	Finalizing MAD Study Protocol	Target start Q4 2025
ART27.13	Interim Phase 2 CAReS Data Reported	+6.4% average weight gain (highest dose)
ART27.13	Interim Phase 2 CAReS Data Reported	4.2% increase in lean body mass

Finance: draft 13-week cash view by Friday.

Artelo Biosciences, Inc. (ARTL) - Canvas Business Model: Customer Segments

You're looking at the customer segments for Artelo Biosciences, Inc. (ARTL) as of late 2025. This company is focused on modulating lipid-signaling pathways, which means their customer base is segmented by the specific, high-unmet-need conditions their pipeline candidates are targeting. Honestly, the near-term focus is heavily weighted toward securing a partner for their most advanced asset, ART27.13, given their cash position of $1.7 million as of September 30, 2025.

The customer segments fall into two main groups: the ultimate end-users (patients) and the strategic partners (pharma/biotech companies) who will help bring the therapies to those patients.

For the patients, Artelo Biosciences, Inc. is targeting several distinct, underserved populations:

• Patients with cancer anorexia-cachexia syndrome (CACS).
• Patients suffering from chemotherapy-induced peripheral neuropathy (CIPN).
• Patients with chronic pain, including those with conditions like osteoarthritis.
• Patients with anxiety, mood, and dermatologic disorders, such as psoriasis.

The other critical segment is the corporate one. Artelo Biosciences, Inc. is actively seeking to engage with global pharmaceutical and biotech companies seeking late-stage assets, especially for ART27.13, following positive interim Phase 2 data. This partnering strategy is viewed as the most value-accretive path forward, potentially avoiding the need for Artelo Biosciences, Inc. to internally fund a Phase 3 trial.

Here's a breakdown of the key indications and the associated product candidates, which directly defines the patient customer segments and the market opportunity you should be tracking:

Product Candidate	Target Indication	Key Customer Segment Data Point	Market/Efficacy Metric
ART27.13	Cancer Anorexia-Cachexia Syndrome (CACS)	No FDA-approved treatment currently exists.	Addressable market greater than $3 billion.
ART27.13	CACS	Interim Phase 2 CAReS trial results (Q3 2025).	Average +6.4% weight gain vs. -5.4% loss on placebo.
ART26.12	Chemotherapy-Induced Peripheral Neuropathy (CIPN)	Phase 1 clinical trial initiated (Q4 2024).	Lead Fatty Acid Binding Protein 5 (FABP5) inhibitor.
ART26.12	Chronic Pain (Osteoarthritis)	Preclinical data in a surgical rat model.	Significantly improved weight-bearing function, sustained up to four weeks.
ART26.12	Anxiety, Mood, Dermatologic (Psoriasis)	Preclinical/Review data published.	Antidepressant-like activity on par with sertraline (Zoloft®) in preclinical models.

You should note that the CACS patient population is quite large; the condition affects up to 80% of patients with advanced cancer. For the corporate segment, the interest from multiple pharmaceutical companies in ART27.13 suggests a strong validation of the data package Artelo Biosciences, Inc. has generated so far.

Also, consider the intellectual property protection for ART27.13, as this directly impacts the value proposition to potential partners: the European Patent Office issued a Notice of Allowance for the intended commercial formulation through 2041. That's a long runway for a potential partner to plan around.

Artelo Biosciences, Inc. (ARTL) - Canvas Business Model: Cost Structure

You're looking at the core expenditures Artelo Biosciences, Inc. (ARTL) faces to keep its clinical pipeline moving forward as of late 2025. These costs are typical for a clinical-stage biopharma company heavily reliant on external funding.

Cost Component	Q3 2025 Amount (USD)	Comparison Context
Research and Development (R&D) Expenses	$1.3 million	Up from $0.3 million in Q3 2024
General and Administrative (G&A) Expenses	$1.8 million	Up from $0.9 million in Q3 2024
Gross Proceeds from Capital Raising (Q3 2025)	$3.4 million total	$0.4 million from ATM + $3.0 million from Public Offering

The cost structure is dominated by the clinical and operational spend required to advance its therapeutic candidates.

• Heavy Research and Development (R&D) expenses, which were $1.3 million in Q3 2025.
• General and Administrative (G&A) costs, totaling $1.8 million in Q3 2025.
• Costs associated with intellectual property protection and maintenance, which are factored into the overall operating expenses, including the potential cost of defending intellectual property disputes.
• Capital raising costs, including professional fees associated with efforts that generated gross proceeds of $3.4 million in Q3 2025 through an At-The-Market Offering Agreement and a confidentially marketed public offering.

The increase in operating expenses for the quarter ended September 30, 2025, was primarily the result of increases in professional fees associated with capital raising efforts and increases in research and development expenditures related to clinical programs. Finance: draft 13-week cash view by Friday.

Artelo Biosciences, Inc. (ARTL) - Canvas Business Model: Revenue Streams

You're looking at the revenue side for Artelo Biosciences, Inc. (ARTL) as of late 2025, and honestly, it's what you expect from a company deep in clinical development. The model is almost entirely reliant on external capital right now, not product sales.

Currently $0.000 in product revenue, typical for a clinical-stage biotech. That zero reflects the focus on advancing the pipeline through trials rather than commercialization.

The primary, immediate revenue driver is capital markets activity. You saw proceeds from equity financing, such as the $3.0 million public offering completed in September 2025. That offering consisted of common stock and pre-funded warrants.

Here's a quick look at the capital raised through financing activities reported around the Q3 2025 period to fund the R&D expenses, which were $1.3 million for the quarter:

Financing Source	Q3 2025 Gross Proceeds	First Nine Months 2025 Gross Proceeds
Public Offering (September 2025)	$3.0 million	$3.0 million
At-The-Market (ATM) Offering	$0.4 million	Not specified separately for YTD
Total Equity Issuance (YTD)	Not specified separately for Q3	$4.39 million
Convertible Notes (YTD)	Not specified	$0.74 million
Warrant Exercises (YTD)	Not specified	$0.13 million

Future milestones and royalty payments from out-licensing agreements represent the potential, non-dilutive revenue stream. While Artelo Biosciences is actively seeking partners, specific dollar amounts tied to future milestones or royalties aren't locked in yet, but that's definitely the goal for long-term sustainability.

Also critical to the cash runway was the capital raised via the At-The-Market (ATM) offering, which generated $0.4 million in gross proceeds during Q3 2025. This ATM program allows the company to sell shares opportunistically.

To be fair, the financing picture for the first nine months of 2025 shows a broader reliance on capital markets to bridge the gap:

• Total equity raised through various issuances in the first nine months of 2025 was $4.39 million.
• Capital secured via convertible notes totaled $0.74 million for the same nine-month period.
• An additional $0.13 million came from warrant exercises year-to-date.